Clinical Progress

Alkahest is conducting multiple ongoing Phase II efficacy trials in diseases with critical unmet needs. Our protein-targeted interventions inhibit the negative biological chronokines that increase with age and our proprietary plasma fractions replenish the positive biological functional chronokines that decrease with age. In addition to our lead assets, other therapeutic targets designed to antagonize or supplement additional chronokine targets are in development.

Product
Indication
ResearchIND EnablingPhase 1Phase 2Phase 3
WetAMD
Neurodegenerative Disease
Inflammatory Disease
Alzheimer's Disease - Mild to Moderate
Alzheimer's Disease - Severe
Parkinson's Disease with Cognitive Impairment
Undisclosed Disease
AKST1210
Undisclosed
Novel Factors
Undisclosed